Symbols

CDNA

CareDx·NASDAQ

--(--)

CDNA fundamentals

CDNA Q4 2025 Earnings

CareDx (CDNA) released its earnings on Feb 24, 2026: revenue was 108.39M (YoY +25.19%), beat estimates; EPS was -0.08 (YoY -105.30%), missed estimates.

Revenue / YoY

108.39M

+25.19%

EPS / YoY

-0.08

-105.30%

Report date

Feb 24, 2026

CDNA Earnings Call Summary for Q4,2025

Revenue Momentum: Q4 2025 revenue up 25% YoY to $108.4M, with Testing Services driving 23% growth. Full-year 2025 revenue $379.8M (+14% YoY).
Strategic Product Launches: AlloHeme (AML/MDS relapse detection) in pivotal trial, AlloSeq Tx11 (HLA typing) launched with IVDR certification.
Operational Excellence: RCM improvements reduce claim rejections by 60%, DSO from 71 to 41 days.
2026 Outlook: $420-444M revenue (+14% YoY midpoint), $30-45M EBITDA. Risks include $15M potential Medicare LCD impact.
Growth Drivers: Epic integrations, cell therapy pipeline, and 8-12% YoY Patient/Digital Solutions growth.

Earnings

EPS

Revenue

Revenue & Expenses

CDNA has released its 2025 Q4 earnings report, with revenue of 108.39M, reflecting a YoY change of 25.19%, and net profit of -4.11M, showing a YoY change of -104.68%. The Sankey diagram below clearly presents CDNA's revenue sources and cost distribution.

Key Indicators

CareDx (CDNA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

CareDx (CDNA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

CareDx (CDNA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

CareDx (CDNA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown